Erratum: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (Leukemia (2012) 26 (149-157) DOI: 10.1038/leu.2011.196)

S. K. Kumar, J. H. Lee, J. J. Lahuerta, G. Morgan, P. G. Richardson, J. Crowley, J. Haessler, J. Feather, A. Hoering, P. Moreau, X. Leleu, C. Hulin, S. K. Klein, P. Sonneveld, D. Siegel, J. Bladeé, H. Goldschmidt, S. Jagannath, J. S. Miguel, R. OrlowskiA. Palumbo, O. Sezer, S. V. Rajkumar

Research output: Contribution to journalComment/debate

4 Scopus citations
Original languageEnglish (US)
Number of pages1
JournalLeukemia
Volume26
Issue number5
DOIs
StatePublished - May 1 2012

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., Leleu, X., Hulin, C., Klein, S. K., Sonneveld, P., Siegel, D., Bladeé, J., Goldschmidt, H., Jagannath, S., Miguel, J. S., ... Rajkumar, S. V. (2012). Erratum: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (Leukemia (2012) 26 (149-157) DOI: 10.1038/leu.2011.196). Leukemia, 26(5). https://doi.org/10.1038/leu.2012.15